相关实验视频

Updated: Jul 2, 2025

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

Published on: February 26, 2019

报告给美国中毒中心的葡萄糖类-1受体激素病例,2017-2022年

Christopher E Gaw^1,2,3, Hannah L Hays^3,4,5, Cydney A Kemp^1,6

¹Center for Injury Research and Policy, The Abigail Wexner Research Institute at Nationwide Children's Hospital, 700 Children's Drive, 43205, Columbus, OH, USA.

Journal of medical toxicology : official journal of the American College of Medical Toxicology

|February 29, 2024

概括

葡萄糖类-1受体激动剂 (GLP-1RA) 中毒中心病例显著增加,其中大多数涉及治疗错误和最小的影响. 然而,严重的结果和医疗保健入院急剧增加,突出需要提高患者和提供者的意识.

科学领域:

药物监督药物监督药物监督
毒理学毒理学毒理学
内分泌学在内分泌学.

背景情况:

类似葡萄糖-1受体激动剂 (GLP-1RAs) 对于控制糖尿病和肥胖至关重要.
了解GLP-1RA暴露的安全概况和流行病学至关重要.

研究的目的:

描述了美国中毒中心报告的GLP-1RA病例的流行病学.
分析GLP-1RA暴露的趋势和2017年至2022年的相关结果.

主要方法:

对报告给国家毒素数据系统 (NPDS) 的单一物质GLP-1RA暴露病例的分析.
数据收集时间从2017年1月1日到2022年12月31日.

主要成果:

报告了5,713例GLP-1RA病例,主要是女性 (71.3%) 由于治疗错误 (79.9%).
严重的医疗结果发生在6.2%的病例中,病例率显著增加 (80.9%) 从2021年到2022年.
从2021年到2022年,医疗机构的入院人数显著增加,重症监护病房的入院人数增加了129.9%,非重症监护病房的入院人数增加了95.8%.

结论:

虽然大多数GLP-1RA暴露会导致最小的影响,但很少有严重的后果或需要医疗保健入院.
报告病例和严重结局的升级率强调了需要加强患者和提供者对GLP-1RA不良影响的教育.
有机会提高对这些日益普遍的药物的认识和安全使用.

关键词:

药物不良事件是药物不良事件.它是GLP-1受体激动剂.利拉格卢提德 (Liraglutide) 是一种类药物.塞马格卢提德 (semaglutide) 是一种类型的有毒性有毒性

更多相关视频

Author Spotlight: An Efficient Methodology to Confidently Differentiate and Characterize Fentanyl Analogs

Author Spotlight: An Efficient Methodology to Confidently Differentiate and Characterize Fentanyl Analogs

Published on: November 8, 2024

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Pharmacovigilance

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...